Science Explorer Back to mapMap
Discussion
Institution · Integrated Oncology (United States)

Most cited papers from Integrated Oncology (United States)

Integrated Oncology (United States)

What are the most cited papers from Integrated Oncology (United States)?

The most cited paper from Integrated Oncology (United States) is "Comprehensive genomic characterization of squamous cell lung cancers" (Peter S. Hammerman et al., 2012), with 4,071 citations. Next come "Somatic mutations affect key pathways in lung adenocarcinoma" (2,758) and "Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial" (1,886).

Showing 50 of 58 papers. Every paper with more than 216 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Comprehensive genomic characterization of squamous cell lung cancers Peter S. Hammerman et al. · Nature Open access339 authors 7 Sep 2012 4,071
2 Somatic mutations affect key pathways in lung adenocarcinoma Li Ding et al. · Nature Open access Oct 2008 2,758
3 Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Michael J. Hallek et al. · The Lancet Oct 2010 1,886
4 Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Ronan Joseph Kelly et al. · New England Journal of Medicine Open access 31 Mar 2021 1,872
5 Sotorasib for Lung Cancers with KRAS p.G12C Mutation Ferdinandos Skoulidis et al. · New England Journal of Medicine Open access 4 Jun 2021 1,862
6 Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer Andrew N.J. Tutt et al. · New England Journal of Medicine Open access 3 Jun 2021 1,744
7 Cytokine release syndrome Alexander Shimabukuro‐Vornhagen, Philipp Gödel, Marion S. Subklewe et al. · Journal for ImmunoTherapy of Cancer Open access 15 Jun 2018 1,701
8 Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions Valentin Goede et al. · New England Journal of Medicine Open access 8 Jan 2014 1,521
9 Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer Alice Tsang Shaw et al. · New England Journal of Medicine Open access 26 Mar 2014 1,479
10 Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Martin Peifer et al. · Nature Genetics Open access 2 Sep 2012 1,435
11 Characterizing the cancer genome in lung adenocarcinoma Barbara A. Weir et al. · Nature Open access 4 Nov 2007 1,128
12 Mutations driving CLL and their evolution in progression and relapse Dan Avi Landau et al. · Nature Open access Oct 2015 1,092
13 Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer Jürgen Wolf et al. · New England Journal of Medicine Open access 2 Sep 2020 1,029
14 Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma Paul Nathan et al. · New England Journal of Medicine Open access 22 Sep 2021 916
15 Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions Kirsten Fischer et al. · New England Journal of Medicine 4 Jun 2019 875
16 Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer Jonathan M. Weiss et al. · Science Translational Medicine Open access 15 Dec 2010 830
17 Generation of transgenic non-human primates with germline transmission Erika Sasaki et al. · Nature May 2009 741
18 First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial Barbara F. Eichhorst et al. · The Lancet Oncology 23 May 2016 631
19 Telomerase activation by genomic rearrangements in high-risk neuroblastoma Martin Peifer et al. · Nature Open access 13 Oct 2015 622
20 Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Barbara F. Eichhorst, Tadeusz Robak, Emili Montserrat et al. · Annals of Oncology Open access 27 Aug 2015 613
21 Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer Myung‐Ju Ahn et al. · New England Journal of Medicine Open access 20 Oct 2023 577
22 Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling Juliann Chmielecki et al. · Science Translational Medicine Open access 6 Jul 2011 536
23 PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR Martin L. Sos et al. · Cancer Research Open access 7 Apr 2009 502
24 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up Johan Vansteenkiste et al. · Annals of Oncology Open access 21 Feb 2014 499
25 Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia Jennifer R. Brown et al. · New England Journal of Medicine Open access 13 Dec 2022 492
26 Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer Peter S. Hammerman et al. · Cancer Discovery Open access 8 Apr 2011 476
27 Cancer cachexia is regulated by selective targeting of skeletal muscle gene products Swarnali Acharyya, Katherine J. Ladner, Lori L. Nelsen et al. · Journal of Clinical Investigation Open access Aug 2004 469
28 Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer Kohei Shitara et al. · Nature Open access 23 Mar 2022 455
29 Genome-wide association studies identify four ER negative–specific breast cancer risk loci The Gene ENvironmental Interaction and breast CAncer (GENICA) Network et al. · Nature Genetics Open access274 authors 27 Mar 2013 422
30 Proteases Induce Production of Thymic Stromal Lymphopoietin by Airway Epithelial Cells through Protease-Activated Receptor-2 Hideaki Kouzaki, Scott M. O’Grady, Christopher B. Lawrence et al. · The Journal of Immunology Open access 26 Jun 2009 360
31 A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population EMBRACE et al. · Nature Genetics Open access185 authors 19 Sep 2010 344
32 Advances in neuro-oncology imaging Karl‐Josef Langen, Norbert Galldiks, Elke Hattingen et al. · Nature Reviews Neurology Review 7 Apr 2017 341
33 Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids Lynnette Fernandez‐Cuesta et al. · Nature Communications Open access 27 Mar 2014 319
34 A translational framework to DELIVER nanomedicines to the clinic Paul Joyce et al. · Nature Nanotechnology Open access 6 Sep 2024 314
35 First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia Barbara F. Eichhorst et al. · New England Journal of Medicine Open access 10 May 2023 308
36 CD74–NRG1 Fusions in Lung Adenocarcinoma Lynnette Fernandez‐Cuesta et al. · Cancer Discovery 27 Jan 2014 295
37 Review on lignin modifications toward natural UV protection ingredient for lignin-based sunscreens My Ha Tran, Dieu-Phuong Phan, Eun Yeol Lee · Green Chemistry 2021 290
38 Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer Christine Marie Lovly et al. · Nature Medicine Open access 31 Aug 2014 269
39 Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors Sandra Ortiz‐Cuaran et al. · Clinical Cancer Research Open access 2 Jun 2016 263
40 Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions Martin L. Sos et al. · Journal of Clinical Investigation Open access 19 May 2009 262
41 Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants Johannes M. Heuckmann, Hyatt Balke‐Want, Florian Malchers et al. · Clinical Cancer Research 22 Aug 2012 261
42 Control of Bcl-2 expression by reactive oxygen species David A. Hildeman, Thomas C. Mitchell, Bruce J. Aronow et al. · Proceedings of the National Academy of Sciences Open access Dec 2003 251
43 A crucial requirement for Hedgehog signaling in small cell lung cancer Kwon-Sik Park et al. · Nature Medicine Open access 9 Oct 2011 250
44 Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04) Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama et al. · Cancer Open access 4 Dec 2017 247
45 PD-L1 expression in small cell neuroendocrine carcinomas Anne Maria Schultheis, Andreas Hans Scheel, Luka Ozretić et al. · European Journal of Cancer Open access 9 Jan 2015 242
46 Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study Valentin Goede, Kirsten Fischer, Anja Engelke et al. · Leukemia 30 Jan 2015 237
47 Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine Open access 10 Jan 2024 236
48 Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases Daniel Abido Galvao, Dennis R. Taaffe, Nigel A. Spry et al. · Medicine & Science in Sports & Exercise Open access 15 Oct 2017 233
49 ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma Maximilian Niyazi, Nicolaus H. Andratschke, Martin Bendszus et al. · Radiotherapy and Oncology Open access 13 Apr 2023 229
50 Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity Katrin S. Reiners, Daniela Topolar, Alexander Henke et al. · Blood Open access 19 Mar 2013 229

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.